Multisystem Inflammatory Syndrome in Children With COVID-19 in Mumbai, India인도 뭄바이에서 COVID-19에 감염된 어린이의 다기관 염증 증후군Observational Study Published on 2020-11-152022-09-11 Journal: Indian pediatrics [Category] MERS, 바이오마커, 임상, 진단, [키워드] age analyzed antibody BNP children conducted Contact Coronary artery COVID-19 criteria death demographics diagnostic dysfunction elevated hospital Immunoglobulin IMPROVE incidence India Inflammatory IVIG Laboratory males median medication medications MIS-C Mumbai myocarditis neutrophilia observational study outcome Patient patients treated positive required RT-PCR Shock significantly higher steroid Steroids Surveillance Symptomatology syndrome Treatment troponin were used WHO criteria with COVID-19 [DOI] 10.1007/s13312-020-2026-0 PMC 바로가기 [Article Type] Observational Study
Distinguishing between typical Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2SARS-CoV-2와 관련된 소아의 다기관 염증 증후군(MIS-C)과 전형적인 가와사키병의 구별Article Published on 2020-11-012022-09-12 Journal: Medical Hypotheses [Category] 진단, [키워드] activate Activation acute respiratory syndrome Bone marrow CD8+ cell children classical Cohort coronavirus COVID-19 debate distinguishing Fc receptor FcR help Hyperinflammatory syndrome immune immune complex Immunoglobulin Immunopathogenesis Inflammatory inflammatory cell inflammatory cells Inflammatory response Intravenous immunoglobulin IVIG Kawasaki disease kill membranes MIS-C monocyte Neutrophils paediatrics Pathogenesis Patient PIMS-TS Platelet Platelets pro-inflammatory recruitment resulting SARS-CoV-2 secreted significantly lower stimulate suppress syndrome these cell thought viral infected cells virus [DOI] 10.1016/j.mehy.2020.110263 PMC 바로가기 [Article Type] Article
The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial중증 코로나바이러스 질환의 치료를 위한 정맥 면역글로불린 감마의 사용 2019: 무작위 위약 대조 이중 맹검 임상 시험Research Article Published on 2020-10-212022-08-13 Journal: BMC Infectious Diseases [Category] MERS, SARS, 임상, [키워드] accompany addition administration assigned clinical Clinical characteristics Clinical outcome clinical trial clinical trials conducted control group coronavirus disease Coronavirus disease 2019 country COVID-19 COVID-19 infection demographics demonstrated disease double-blind effective Efficacy evaluate Immunoglobulin IMPROVE in-hospital mortality in-hospital mortality rate information initial initial treatment initial treatment) initial treatments Intravenous immunoglobulin IVIG Laboratory Laboratory test Laboratory tests medication mortality rate multicenter multivariate regression analysis Occurrence Patient Placebo placebo-controlled Randomized Randomly reduce mortality rate Registered registry required respond Result Sample size severe cases severe coronavirus disease Severe COVID-19 Infection Severe infection significantly significantly lower standard treatment statistically Study protocol subject subjects Treatment two groups were recorded [DOI] 10.1186/s12879-020-05507-4 PMC 바로가기 [Article Type] Research Article
Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort studyOriginal Article Published on 2020-10-142022-10-31 Journal: Clinical & Translational Immunology [Category] COVID-19, [키워드] administration Analysis carried China clinical Clinical efficacy clinical study Cohort coronavirus disease Coronavirus disease 2019 COVID‐19 COVID‐19 patient COVID‐19 Critical decrease disease dosage early stage Efficacy enrolled Evidence exhibited High dose ill patient Immunoglobulin IMPROVE Inflammatory response information Intravenous immunoglobulin IVIG Mortality multicenter objective organ function outbreak Patient patient selection patients per day Primary outcome Prognosis provide reduce reduction in Result retrospective cohort study SARS‐CoV‐2 infection SARS‐CoV‐2 secondary outcome significantly the disease therapy treat Treatment [DOI] 10.1002/cti2.1192 PMC 바로가기 [Article Type] Original Article
Intravenous immunoglobulin therapy in COVID-19-related encephalopathyCOVID-19 관련 뇌병증에서 정맥 면역글로불린 요법Original Communication Published on 2020-10-082022-09-12 Journal: Journal of Neurology [Category] MERS, SARS, 진단, [키워드] adverse event adverse events age Agitation all subjects anti-cytokine anti-inflammatory action brain MRI Case series case sery cell count clinical Clinical efficacy collected data commenced Complete COVID-19 CSF CSF analysis delirium demonstrated disease course driven by effective Efficacy Efficacy and safety Encephalopathy extrapyramidal females hospital Hospitalized Immunoglobulin impaired consciousness initial Intravenous immunoglobulin Invasive mechanical ventilation Italian IVIG manifestation neurological manifestations Neuropsychiatric non-specific objective Patient patients patients with COVID-19 preliminary finding protein levels required respiratory distress Result RT-PCR Safe SARS-CoV-2 Severe respiratory distress suffered supplementary material Symptom tested therapy treated Treatment [DOI] 10.1007/s00415-020-10248-0 PMC 바로가기 [Article Type] Original Communication
Kawasaki Disease and COVID-19Review Published on 2020-09-212022-10-31 Journal: Mediterranean Journal of Rheumatology [Category] COVID-19, [키워드] acute respiratory syndrome Admission Artery Atypical Kawasaki disease bleeding childhood children coronavirus COVID-19 Cytokine storm described excluded feature Fever IL-1 IL-6 Immunoglobulin include Inflammation inflammatory disease inhibitors intensive care unit intravenous IVIG Kawasaki-COVID-19 Kawasaki-like disease macrophage activation syndrome Methylprednisolone MIS-C multi-organ dysfunction myocarditis paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 peeling SARS-CoV-2 Sepsis Shock skin rash staphylococcal Support syndrome tongue Toxic shock syndrome Vasculitis [DOI] 10.31138/mjr.31.3.268 PMC 바로가기 [Article Type] Review
A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19Article Published on 2020-09-052023-06-16 Journal: Transfusion and apheresis science : official journ [Category] MERS, SARS, [키워드] convalescent plasma COVID-19 IVIG plasma exchange [DOI] 10.1016/j.transci.2020.102936 PMC 바로가기
Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case seriesResearch article Published on 2020-09-012022-10-05 Journal: Virology [Category] SARS, 치료법, [키워드] administration All the patient case sery clinical condition Clinical symptoms COVID-19 COVID-19 patient Deterioration diagnosed discharged dose Effect high mortality High-dose hospital IMPROVE improvement Intravenous immunoglobulin IVIG morbidity O2 Saturation Patient PCR populations Prevalence Prevent prevented progression pulmonary lesion receive reported severe symptom standard treatment the disease therapeutic therapeutic response treated Treatment [DOI] 10.1016/j.virol.2020.05.006 [Article Type] Research article
High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical EffectsImmunology Published on 2020-07-142022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] Asymptomatic Autoimmune blood product caused clinical clinical evidence Concentration confirmed case COVID-19 COVID-19 outbreak develop Effect healthy donor high-dose IVIg highlight Hypothesis IgG Immunoglobulin immunomodulatory effect immunopathological imperative in viral infected individual Inference inflammatory disease Intravenous immunoglobulin IVIG mechanism mechanism of action Mild symptom Mortality novel coronavirus SARS-CoV-2 outbreak pandemic Patient Pneumonia Respiratory failure SARS-CoV-2 severe COVID-19 severe SARS-CoV-2 supportive care therapeutic therapeutic inference therapy Treatment treatment for COVID-19 Viral pneumonia while WHO [DOI] 10.3389/fimmu.2020.01660 PMC 바로가기 [Article Type] Immunology
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-07-132022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 24 hour 48 hour Activation acute lung injury acute pneumonia acute respiratory distress syndrome Administered Adult age all-cause mortality Amendment antibodies antibody Antibody test anticipated antiviral therapy approval ARDS assessment assigned baseline Biomarker Blood cardiac disease Care change class Clinical improvement clinical study clinical trial complement Complement inhibitor component Computed tomography concealed Concentration conducted Confirmed Controlled coronary syndrome COVID-19 criteria current Day diagnosis of SARS-CoV-2 dialysis discharge dissemination dose Duration Efficacy element eligibility Endotracheal intubation EU Clinical Trial EudraCT evaluate the effect expected failure female patient Final fraction France Germany greater half-live hospital Hospitalization humanized Hypercoagulable state Immunoglobulin Infection Inflammatory inhibitor initiated intensive care Intubated intubation invasive Invasive mechanical ventilation investigator IVIG Japan Lung injury mechanical ventilation medication monoclonal multicenter Neisseria meningitidis Non-invasive number objective Open-label original outcome oxygen participant Patient patients randomized patients with COVID-19 Period peripheral capillary phase Placebo Pneumonia polymerase chain positive airway pressure presenting progression protocol randomised randomised controlled trial randomization randomization list Randomized randomized controlled study Randomly Ravulizumab receive recruitment registry Remdesivir renal respiratory respiratory distress Respiratory distress syndrome routine clinical care Safety screened Screening secondary Serious Adverse Events serum severe acute respiratory distress syndrome coronavirus 2 Severe acute respiratory syndrome severe COVID-19 severe pneumonia SOFA Spain SpO2 Sponsor stratified Study protocol supportive care survival The United States therapy time Treatment treatment-emergent adverse event Ultomiris United Kingdom ventricular Viral website with COVID-19 X-ray [DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter